Sweden Cancer Diagnostics Market Size & Outlook, 2023-2030
Sweden cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Sweden cancer diagnostics market highlights
- The Sweden cancer diagnostics market generated a revenue of USD 1,270.2 million in 2023 and is expected to reach USD 1,918.5 million by 2030.
- The Sweden market is expected to grow at a CAGR of 6.1% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 1,270.2 million |
| Market revenue in 2030 | USD 1,918.5 million |
| Growth rate | 6.1% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, Sweden accounted for 1.2% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 9,637.9 million by 2030.
Consumables was the largest segment with a revenue share of 59.94% in 2023. Horizon Databook has segmented the Sweden cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Continuous developments by local companies can contribute to the country’s market growth. In December 2022, Elypta, a Swedish market player, announced plans to develop an MCED using glycosaminoglycan biomarkers.
Elypta began clinical research in 2022 to confirm the efficacy of glycosaminoglycans as metabolic indicators for MCED. In addition, in June 2021, SAGA Diagnostics announced raising USD 11.48 million to accelerate the marketing of ultrasensitive cancer liquid biopsies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Sweden cancer diagnostics market size, by product, 2018-2030 (US$M)
Sweden Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
